Wondfo Biotech

What Wondfo Biotech does

Wondfo Biotech is a Chinese in vitro diagnostics (IVD) and point-of-care testing (POCT) manufacturer headquartered in Guangzhou, China, publicly listed on the Shenzhen Stock Exchange (szse:300482). Founded in 1992, the company has built a portfolio of eight diagnostic technology platforms: colloidal gold, immunofluorescence (Finecare series), chemiluminescence, coagulation, blood gas, molecular diagnostics, pathology (IHC), and HPLC hemoglobin testing. Each platform pairs proprietary analyzers with reagent consumables, and the Finecare meter series reportedly holds the largest installed base across all levels of medical institutions in China.

The company's go-to-market combines direct enterprise sales through 20 global subsidiaries with regional distribution partnerships, reaching healthcare institutions in 150 countries and regions. Revenue is generated through a hardware-plus-consumables model: initial placement of analyzers creates a recurring stream of proprietary reagent sales, which is the dominant IVD economics. End customers include hospitals, clinics, and laboratories for routine clinical testing, and international public health organizations for WHO-prequalified infectious disease screening. The company holds WHO prequalification for infectious disease diagnostics and was first-batch approved in China for COVID-19 antibody testing.

Wondfo employs more than 3,000 people globally, including 800 researchers, and has expanded its platform portfolio aggressively from 2022 onward, adding chemiluminescence, coagulation, molecular diagnostics, blood gas, pathology, and HPLC hemoglobin offerings within roughly three years. Reported revenue (per the financial table labeled in $M) peaked at approximately $824M in 2022 during COVID-19 demand and has since declined to roughly $298M in 2025, reflecting post-pandemic normalization. Recent strategic emphasis has shifted toward chronic disease (HbA1c, Vitamin D), antibiotic stewardship (CRP campaign), and global clinical-society partnerships such as the IFCC FEN collaboration formalized in March 2026.

Name

Wondfo Biotech

Legal name

Wondfo Biotech

Website

https://en.wondfo.com.cn

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Wondfo Biotech is a Chinese publicly listed IVD and point-of-care diagnostics manufacturer (Shenzhen: 300482) offering eight diagnostic platforms across immunofluorescence, chemiluminescence, molecular, and blood gas testing, serving hospitals, clinics, and laboratories in 150 countries through 20 subsidiaries.

Ownership category

akta.pro rank

Headquarters

HQ city

Huangpu

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. POCT Diagnostic Devices and Reagents: Wondfo generates revenue through the sale of diagnostic instruments and corresponding reagent kits across multiple technology platforms including colloidal gold, immunofluorescence, chemiluminescence, coagulation, blood gas, molecular diagnostics, pathology, and HPLC hemoglobin testing. The business model combines hardware sales (analyzers) with recurring reagent consumable revenue.
2. Recurring Reagent and Consumable Sales: Following initial instrument placement, Wondfo derives recurring revenue from proprietary reagent kits and consumables tailored for their diagnostic platforms. This creates a consumables-based revenue stream typical of IVD companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

Wondfo Biotech manufactures and sells Point-of-Care Testing (POCT) diagnostic instruments and reagent kits across eight proprietary technology platforms — Colloidal Gold, Immunofluorescence (Finecare), Chemiluminescence, Coagulation, Blood Gas, Molecular Diagnostics, Pathology, and HPLC Hemoglobin. The company combines hardware (analyzers) sales with recurring reagent and consumable revenue, supplying hospitals, clinics, and laboratories in 150 countries.

Product overview

Wondfo Biotech is a leading Point-of-Care Testing (POCT) company specializing in the In Vitro Diagnostics (IVD) industry. The company operates a multi-platform product portfolio comprising eight distinct technology platforms: Colloidal Gold Platform (for infectious disease, fertility, and DOA testing), Immunofluorescence Platform (Finecare Meter series with 50+ reagents for cardiovascular, inflammation, kidney, hormones, thyroid, diabetes, and tumor detection), Chemiluminescence Platform (single-dose immunoassay), Coagulation Platform (optical blood coagulation analyzer testing PT, APTT, TT, FIB, and ACT simultaneously), Blood Gas Analyzer BGA-102 (for oxygenation, pH, and electrolyte balance testing in 30 seconds), Molecular Diagnostics Platform (lyophilized RT-PCR reagents for COVID-19), Pathology Platform (PA-3600 IHC Staining System), and HPLC Hemoglobin Platform (Truth-H80E for HbA1c testing). These platforms are complemented by solution offerings including the 1㎡ POCT Lab, Finecare™ Vitamin D, Wondfo CRP Campaign, International Public Health Solutions with WHO prequalification, and COVID-19 Total Solution. Founded in 1992 in Guangzhou, the company employs over 3000 people with 800 researchers serving 150 countries and regions through 20 subsidiaries.

Differentiator

Problem solved

Functional benefit

Brands

• Finecare: Finecare Meter series - immunofluorescence platform with 50+ reagents and 7 high-performance devices focusing on cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor detection
• Wondfo Truth-H80E

Products and services

• Colloidal Gold Platform

Quantifiable outcome

• Blood Gas Analyzer BGA-102 delivers results in 30 seconds
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• IFCC (International Federation of Clinical Chemistry and Laboratory Medicine)coreStrategic or Co-development Partner · 1 March 2026Wondfo has partnered with IFCC through the IFCC FEN (Fellowship of Emerging Scientists/National Societies) program to advance global laboratory medicine. This strategic collaboration focuses on supporting emerging scientists and strengthening professional networks in clinical chemistry and laboratory medicine worldwide. The partnership was formalized in March 2026 with a memorandum of cooperation.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Danaher (Beckman Coulter Diagnostics): Global diagnostics giant operating in clinical chemistry, immunoassay, and hematology. Competes with Wondfo in central lab and POCT immunochemistry segments serving similar hospital customers.
• Roche Diagnostics: Global IVD leader with cobas Liat PCR POCT platform and broad immunochemistry menu. Competes in chemiluminescence and POCT molecular segments with significantly larger R&D and clinical evidence base.
• Becton Dickinson (BD): Global medical technology company with BD Veritor rapid diagnostic platforms and extensive microbiology/hospital diagnostics portfolio. Comparable in hospital POCT and infectious disease rapid testing.
• Siemens Healthineers: Global IVD and imaging giant with Atellica and epoc POCT blood gas platforms. Overlaps with Wondfo in blood gas, immunoassay, and clinical chemistry hospital markets.
• QuidelOrtho: U.S. diagnostics company specializing in rapid immunoassay and specialty POCT including Sofia platform. Direct overlap with Wondfo's colloidal gold and rapid infectious disease testing franchise.
• Abbott Point of Care: Abbott's i-STAT and rapid diagnostics division is the global leader in hospital point-of-care blood gas and immunoassay testing. Comparable blood gas and POCT platforms serving similar hospital customer base globally.

Direct peers

• Snibe Diagnostic: Shenzhen New Industries Biomedical Engineering is a Chinese IVD specialist focused on chemiluminescence immunoassay systems with global distribution. Directly comparable in POCT reagent/instrument model and Chinese export orientation.
• Autobio Diagnostics: Chinese IVD company with strong chemiluminescence, microbiology, and clinical chemistry platforms. Competes head-to-head with Wondfo in Chinese hospital immunoassay and POCT markets.
• Maccura Biotechnology: Chinese IVD player with biochemistry, chemiluminescence, POCT, and molecular diagnostics platforms. Comparable product portfolio breadth and Chinese hospital sales motion.
• Mindray Medical: China's largest medical device company with a substantial IVD/POCT division spanning immunoassay, hematology, and chemistry analyzers. Most directly comparable Chinese-headquartered POCT/IVD peer with similar platform breadth and global hospital sales motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/wondfobiotech
• YouTubeyoutube.com/channel/UCiJc9BlYVbtsHNoxLkupWYA
• Facebookfacebook.com/WondfoOfficial
• LinkedInlinkedin.com/company/wondfo
• Instagraminstagram.com/wondfo.biotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wondfo Biotech